Inflammatory Bowel Disease: Diagnosis and TherapeuticsRussell D. Cohen One of the most vivid memories from my medical school training was seeing my first surgical operation on a patient with Crohn’s disease. The senior surgeon at Mount Sinai Hospital in New York City, the same institution at which Burrill Crohn, Leon Ginzburg, and Gordon Oppenheimer had first described the disease “terminal ileitis,” had - doubtedly done countless operations on patients with inflammatory bowel disease in the past. Yet as we both gazed down into the patient’s open abdomen, at the “creeping fat” that seemed to be wrapping its sticky fingers around the young man’s intestines, he stated, “this is the m- tery of Crohn’s disease—no two patients are ever the same. ” What is it about the inflammatory bowel diseases, Crohn’s disease, and ulcerative colitis, that we find so intriguing? Is it the young age of the patients, many who are younger than even the medical students - tending to them? Or is it the elusive etiology, the theory of a “mystery organism” that has yet to be identified? Perhaps it is the familial pattern of disease, where many patients have relatives with similar diseases, yet in some instances only one of a pair of identical twins is affected. Regardless of the cause, these chronic diseases with a typically early age of onset, result in a long-term commitment of the patient, their fa- lies, friends, health care providers, researchers, employers, and even health care insurers and other health-related industries. |
Contents
11 | |
List of Contributors ix | 17 |
Etiology and Pathogenesis | 33 |
Joseph B Kirsner MD PhD DSCI | 38 |
Genetics of Inflammatory Bowel Disease | 65 |
Presentation and Diagnosis | 75 |
Radiological Findings | 91 |
JEANETTE NEWTON KEITH MD Section of GINutrition Department | 99 |
Surgical Management | 157 |
Ostomy Care | 201 |
NutritionalMetabolic Issues in the Management | 231 |
Extraintestinal Manifestations | 259 |
Cancer in Inflammatory Bowel Disease | 279 |
GenderSpecific Issues | 295 |
Economics of Inflammatory Bowel Disease | 307 |
centuries and in the mix of the infectious colitides 1 During the latter | 317 |
Other editions - View all
Common terms and phrases
abdominal abscesses anastomosis antibodies antigen approx ASCA assessment associated azathioprine biopsies cancer CD and UC CD patients cells chronic Clin clinical colectomy colonoscopy complications corticosteroids Crohn’s colitis Crohn’s disease crypt cyclosporine cytokines diagnosis disease activity distal doses dysplasia effective elemental diet endoscopic enteral nutrition epidemiological epithelial evaluation extraintestinal manifestations factors fecal fistulas Gastroenterology gastrointestinal gene genetic histologic ileal ileostomy ileum immune incidence increased inflammation inflammatory bowel disease infliximab intestinal involvement IPAA lesions markers medical therapy mesalamine Michelassi F mucosal neutrophils normal nutrition support oral ostomy pANCA pathogenesis patients with Crohn’s patients with IBD pediatric perianal peristomal postoperative pouching system pouchitis preoperative present primary sclerosing cholangitis proctocolectomy protein rates rectal recurrence relapse remission reported resection risk role serum skin barrier small bowel steroid stoma strictureplasty strictures studies sulfasalazine Surg surgery surgical symptoms Targan therapeutic tion treatment UC patients ulcerative colitis